Protonix Settlement Leaves Question Of How Jury Would Assess At-Risk Launch Damages
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva and Sun are to pay $2.15 billion for their at-risk launch of generic versions of Pfizer’s Protonix; Pfizer says figure represents lost profits and lost royalties from the three years the product faced premature generic competition.
You may also be interested in...
ANDA Litigation Soars In 2014-2015; Patent Office Petitions Also Jump
Purdue's OxyContin and Amarin's Vascepa lead the list of targets as an increasing number of generic firms take up litigation.
Pfizer Litigation Strategy: Business Focus, Legal Alliance Drive Successes
Pfizer’s litigation department scored several key victories in the past year, which the company chalks up to its business approach to running cases and the teamwork of its law firms.
Teva CFO Sees New Products Coming From Its NTEs & Israel’s R&D Hub
Teva’s CFO says the world’s top generics maker is entering a growth period buoyed by emerging markets and an expanding pipeline that will include re-purposed drugs, allowing the company to offset revenue lost from patent expiries. He also believes innovative R&D in home market Israel will soon enjoy a renaissance.